The United Kingdom bought 20,000 doses of smallpox vaccine. It’s about the product Imvanex of the Danish Bavarian Nordic, of which we had already spoken. It will be offered to ‘identified close contacts of people diagnosed with monkeypox, to reduce the risk of symptomatic infections and serious illnesses ». The third generation product is approved in the United States and Canada under the trade names of Jynneos and Imvamune respectively. And in both countries it is authorized for both human smallpox, which was eradicated in the 1970s, and for that of monkeys. In Europe, however, it is known just as Imvanex and theindication is for human smallpox onlyalthough in the past it has been authorized to administer it in response to cases of monkeypox.
And while the France indicates administration to adults at risk of exposure, including healthcare professionals, the Undersecretary for Health Andrea Costa reassures: «On the monkeypox we must say clearly that we are not facing an emergencyHe explained to RaiNews24. Adding that according to the Higher Institute of Health, our country would have “over 5 million doses»Of smallpox vaccine,« so we are prepared to proceed if necessary, if necessary ». While waiting to understand more, it should still be Imvanex.
“We are facing a situation that must be monitored and monitored – added Costa – the disease is not comparable to Covid and it does not affect the entire population because those who have been vaccinated against smallpox, about 40% of the population, already have one protection of approximately 85%. So it’s a different scenario that needs to be monitored. Our government is also monitoring through a task force set up at the Higher Institute of Health and in collaboration with the Regions and the EU ».
Meanwhile, according to one circular of the Ministry of Health in Italy they will be needed at least 21 days of close contact monitoring starting from the last exposure with a patient or with its contaminated materials during the infectious period. As for the vaccinationthe document explains that post-exposure (ideally within four days of exposure) “can be considered for higher risk contacts such as health workers, including laboratory staff, after careful evaluation of the risks and benefits “. Instead i medications, including specific antivirals, can be considered “in the context of experimental or compassionate use protocols, particularly for those who have severe symptoms or who may be at risk of poor results, such as immunosuppressed people.” For now, in short, we are a step behind the United Kingdom and France where, in fact, the vaccine will be offered to close contacts regardless of the fact that they may develop symptoms.
Also according to Francesco Vaiageneral director of Inmi Spallanzani of Rome, of monkeypox “we don’t have to worry”. The scientist spoke about it at a meeting at the Foreign Press Association. “Of the cases we have ascertained, the first are already healing – reports theAdnKronos – my goal is to give people strength to fight the disease and not to depress them ». Vaia added that “we have made a leap forward: it is transmitted from man to man. The patients ascertained to Spallanzani are six, we have the virus in culture and in some days we will have the isolate of the virus in hand and we could carry out complete experiments. This is smallpox distant relative of the one we have known, what manifests itself today is a disease that we are able to contain at this time. Are those who did anti-smallpox before 1981 protected by monkeypox? Probably to a large extent yes, but first the viral isolate must be verified and then we will be able to answer the question if the vaccination covers and in what percentage “.
Monkey pox: symptoms, transmission, treatment and mortality. Everything you need to know about the virus
Smallpox of the monkeys, Pregliasco: «It is important to talk about it, but without alarmism. Here’s what’s good to know about the virus “
Source: Vanity Fair
